Centessa, based in Cambridge, Mass. and London, launched as a “novel asset-centric pharmaceutical company.”

Basel-based Lonza AG is moving to sell the company’s Lonza Specialty Ingredients division to private equity firms Bain Capital and Cinven for CHF 4.2 billion ($4.7 billion), completing a planned pivot to focus on Lonza Pharma, Biotech & Nutrition business. 

The lack of face-to-face meetings during the Covid-19 pandemic caused the U.S. Food and Drug Administration to implement regulatory workarounds to stay on top of drug and biologics approvals, and a news feature published in Nature Biotechnology suggests these workarounds are here to stay.

Seattle-based AltPep Corporation raised $23.15 million in a Series A financing round to take the company’s breakthrough amyloid targeting platform to development.

Publicly traded companies that have been heavily involved in developing therapies and vaccines for Covid-19 have experienced significant spikes in their stock prices from March 2020 to January 2021, including Germany’s BioNTech, which surged 187% in one year.

DBV Technologies unveiled a global restructuring plan that will result in a reduction of more than 200 jobs.

German biotech firm CureVac agreed to an alliance with drugmaker Bayer to get global support in seeking approval for the company’s experimental Covid-19 vaccine and for distribution, the daily Bild reported.

Moderna Inc.’s coronavirus vaccine mRNA-1273 became the second to receive emergency use authorization (EUA) from the U.S. Food and Drug Administration, welcome news to a nation with a staggering Covid-19 death toll of more than 307,000 lives lost.

Four more companies secured their place on the stock ticker in a record-breaking year before 2020 comes to a close.  

Ten Covid-19 vaccines could be available by the middle of 2021 if they win regulatory approval, but their inventors need patent protection, the head of the global pharmaceutical industry group said.